A panelist discusses a typical lower-risk myelodysplastic syndrome case managed with luspatercept over ...

Myelodysplastic syndromes are haematopoietic stem cell neoplasms with characteristic dysplasia in the blood and bone marrow cells resulting in ineffective haematopoiesis, cytopenias, and increased ...

12. Stark AN, Scott CS, Bhatt B, Roberts B. Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia. J Clin Pathol 1986;39:728-730. 13. Bonati, A, Delia D, Starcich R. Progression of a ...

NORTH CHICAGO, Ill., June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly ...

Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short By Kevin Dunleavy Jun 16, 2025 4:23pm AbbVie Roche Venclexta (venetoclax) multiple myeloma ...

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic ...

By Denny Jacob. AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona).

NORTH CHICAGO, Ill., June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly ...

The Myelodysplastic syndromes group at the Josep Carreras Leukaemia Research Institute has enhanced the characterisation of the first cell model capable of faithfully representing this disease.

Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules ...

First-line luspatercept may offer significant advantages over erythropoiesis-stimulating agents (ESAs) for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), according to a ...